For further information, please contact:Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: firstname.lastname@example.org Schond GreenwayVP, Investor RelationsMesoblast LimitedT: +1 212 880-2060 E: Schond.Greenway@mesoblast.com
NEW YORK and MELBOURNE, Australia, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first quarter ended September 30, 2016 and provide a corporate update beginning at 5:00 pm Eastern Time on Monday, November 14, 2016 and 9:00 am Australian Eastern Daylight Time on Tuesday, November 15, 2016. To access the call, dial 1 855 881 1339 (toll-free US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia). The conference identification code is 912575. The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/58214386d5f1311b35bd36a6 The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the Investor page on the Company's website - www.mesoblast.com About MesoblastMesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.